Pancreatic cancer is one of the most lethal human malignancies, partly because of its propensity for metastasis. However, the mechanisms of metastasis in pancreatic cancer remain unclear. Oxidized low density lipoprotein receptor 1 (OLR1), a lectin-like scavenger receptor that recognizes several ligands, such as oxidized low-density lipoprotein, was previously reported in cardiovascular and metabolic diseases. The role and mechanism of OLR1 in pancreatic cancer is unclear. In the present study, we found that OLR1 expression was significantly higher in pancreatic cancer tissues than that in adjacent normal tissues and closely associated with reduced overall survival. OLR1 promoted proliferation and metastasis of pancreatic cancer cells in vitro and in vivo. Mechanistically, OLR1 increased HMGA2 transcription by upregulating c-Myc expression to promote the metastasis of pancreatic cancer cells. In addition, pancreatic cancer patients with high expression of OLR1-c-Myc-HMGA2 on March 6, 2020.
promoters of target genes to regulate gene expression. c-Myc plays an important role in the initiation and development of cancer by its placement at the crossroads of many cancer-related signaling pathways [19, 20] . c-Myc promotes cell metastasis in many cancers and is regulated by many factors [19] . However, the relationship between OLR1 and c-Myc is unclear.
High mobility group AT-hook 2 (HMGA2), a member of high mobility group A, plays a critical role in growth during embryonic development but is expressed at low levels in adult tissues [21] . However, HMGA2 has been reported to be upregulated in many cancers [21] [22] [23] . HMGA2 mainly functions as a transcription coregulator by modifying chromosomal architecture or recruiting other transcription-associated proteins to regulate the differentiation and proliferation of cells [24] . HMGA2 was recently shown to promote metastasis in cancer by regulating EMT and enhancing TGFβ signaling [21] [22] [23] 25] .
In the present study, we investigated the role and potential function of OLR1 in pancreatic cancer. We found that OLR1 expression was highly expressed in pancreatic cancer tissues and that OLR1 promoted metastasis of pancreatic cancer cells through increasing transcription of HMGA2 through c-Myc. Our results identified a novel OLR1-c-Myc-HMGA2 axis and show its potential as a combined biomarker of pancreatic cancer patient prognosis.
Materials and Methods Cell lines and clinical specimens
The human pancreatic cancer cell lines Bxpc-3 and Mia PaCa-2 were purchased from the American Type Culture Collection (ATCC) and cultured in Dulbecco's Modified Eagle Medium (DMEM) or RPMI1640 with 10% fetal bovine serum (FBS) (HyClone, UT, USA) in a 5% CO 2 cell culture incubator at 37°C. All cell lines were authenticated using high resolution small tandem repeats (STR) profiling at Department of General Surgery Laboratory. The mycoplasma of cells was examined by MycoSensor PCR Assay Kit (Cat # C0301S; Beyotime, China). Cells were grown for 15 passages and then replaced with fresh stocks. The 99 clinical pancreatic cancer specimens were obtained from patients who received surgery in the Peking Union Medical College Hospital from January 2004 to November 2008; the specimens were used for the construction of a TMA. This research was approved by the Ethics Committee of Peking Union Medical College Hospital and written informed consent was obtained from each patient.
IHC analysis
Antibodies against OLR1, HMGA2 (Proteintech Group, Chicago, IL, USA) and c-Myc (Cell Signaling Technology, USA) were used to perform IHC analysis in the TMA as described previously [26] . Two experienced pathologists independently assessed the results. Staining intensities were graded as 0 (negative), 1 (low), 2 (medium), or 3 (high), while the staining extent was scored from 0 to 100%. The final IHC staining score was calculated as intensity score × percentage score × 100.
TCGA, GEO and ENCODE datasets
Data from the TCGA, the GEO database (accession numbers: GSE28735 and GSE71729) and ENCODE were used [27] .
Constructs and cell transfection siRNA targeting OLR1 and a scramble control siRNA were purchased from Guangzhou RiboBio Co., LTD. (Guangzhou, China). The full length OLR1 cDNA was subcloned into the pcDNA 3.1 empty vector to generate the pcDNA3.1-OLR1 expression construct. Transient transfections were performed using Lipofectamine 3000 (Invitrogen) according to the manufacturer's protocol. The OLR1 overexpression construct and OLR1 shRNA were packaged into lentivirus, and cells were infected to establish cells that stably express OLR1 or shRNA targeting OLR1. Cells were then selected by puromycin (1 μg/ml) for 7 days. The siRNA sequences are listed in Supplementary Materials.
Western blot analysis
Western blot analysis was performed as described previously [28] . Briefly, protein lysates (20 μg) were separated using SDS-PAGE, and primary and secondary antibodies were applied to detect target proteins. An enhanced chemiluminescence assay was used to visualize protein bands. Primary antibodies targeting OLR1 and HMGA2 were purchased from Proteintech Group (Chicago, IL, USA) and c-Myc and β-actin antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA).
qRT-PCR
TRIzol reagent (Invitrogen) was used for the extraction of total RNA and cDNA synthesis was performed using the Takara First Strand cDNA Synthesis Kit following the manufacturer's instructions. qRT-PCR assays were performed independently at least three times. The PCR primers are listed in the Supplementary Materials.
RNA-seq and data analysis
A RNeasy mini kit (Qiagen, Germany) was used for the extraction of total RNA. The directional (stranded) libraries were generated using an Illumina platform for the paired-end sequencing of Bxpc-3 cells. Cuffdiff was used to obtain the sequence count data [fragments per kilobase of transcript per million mapped reads (FPKM) values] to conduct differential expression analysis. Shanghai Biotechnology Corporation performed the library construction and sequencing.
ChIP assay
ChIP assays were performed using a Chromatin Immunoprecipitation (ChIP) Assay Kit (Millipore, 17-295) according to the manufacturer's instructions. Briefly, c-Myc protein was immunoprecipitated from whole cell lysates by A/G magnetic beads conjugated to anti-c-Myc antibody (Cell Signaling Technology). Quantitative ChIP was performed using an ABI StepOne Plus with SYBR Green dye. Primers spanning every region comprising c-Myc binding elements 1 or 2 were designed and used for ChIP-qPCR. The primer sequences are listed in the Supplementary Materials.
Dual Luciferase Reporter Assay
A Dual Luciferase Reporter Assay System (Promega) was performed as previously described [22] . Briefly, cells (1×10 3 cells/well) were plated in a 96-well plate. After 24 h, the cells were co-transfected with 0.2 μg expression vector plasmid or 0.02 nmol siRNA, 0.2 μg promoter reporter plasmid, and 0.002 μg SV40 plasmid using Lipofectamine 3000 (Invitrogen) according to the manufacturer's instructions. After 48 h, cells were lysed using lysis buffer and the lysates were centrifuged at maximum speed for 1 min in an Eppendorf microcentrifuge. The Dual Luciferase Reporter Assay System was used to detect the relative luciferase activity of the samples, and the transfection efficiencies were normalized according to Renilla activity.
Proliferation assays
Cell Counting Kit-8 (CCK-8) reagent (Dojindo, Tokyo, Japan) was used to perform growth assays following the manufacturer's protocol. Cells were seeded into 96-well plates (1,000 cells/well). At 0, 24, 48, 72, and 96 h later, CCK-8 (10 μl/well) was added and cells were cultured for an additional 2.5 h at 37°C. The optical density (OD) was measured as the relative cell number at a wavelength of 450 nm (OD450) with a microplate reader.
Cell migration and invasion assays
Cell migration and Matrigel cell invasion assays were conducted as described previously [26] . In brief, polycarbonate membranes with 8-μm pores were coated with 0.5 mg/ml Matrigel (BD Biosciences) for 6 h. After the membranes were rehydrated, 4.0×10 4 pancreatic cancer cells in DMEM without FBS were placed into the upper chamber of a Transwell unit, and DMEM with 10% FBS was applied as a chemoattractant in the lower chamber. After 24 h, the migrated or invaded cells were fixed by 4% paraformaldehyde and stained with hematoxylin and eosin. After the membranes were dried, the numbers of migrated/invaded cells were counted in 10 low-power fields (magnification, ×100). The mean values were determined in triplicate assays. All experiments were performed at least twice independently.
Wound-healing assay
Cells were seeded into a 12-well plate and then incubated overnight in complete medium. A scratch wound was created in the cell monolayer with a sterile 200 μl pipette tip and the detached cells were removed. The cells were then incubated in 1% FBS medium, and images were captured at 6, 12, 18, and 24 h later. The relative distance of cell migration from the wound at 0 h was determined as the migration distance, as published previously [26] . guidelines of Peking Union Medical College (Beijing, China). For in vivo imaging, human pancreatic cancer cells were infected by lentivirus carrying a firefly luciferase cassette as well as puromycin resistance gene. Cells expressing firefly luciferase (1×10 6 ) were inoculated in situ or intravenously or intrasplenically into mice and monitored by an IVIS imaging system, as published previously [26, 29] .
Xenograft tumor mouse models

Statistical analysis
Each experiment was repeated at least three times. Data were measured by Student's t-test (two-tailed) and analyzed using one-way ANOVA. All statistical tests were performed using the Statistical Program for Social Sciences (SPSS16.0 for Windows, USA) and were two-sided. P value of <0.05 was regarded as statistically significant. GraphPad Prism 6 software (GraphPad, USA) was used to create all graphs.
Results
OLR1 expression is upregulated in pancreatic cancer specimens
We first detected the expression of OLR1 in a tissue microarray (TMA) containing 99 pancreatic cancer tissues and 62 normal pancreatic tissues using immunohistochemistry (IHC). OLR1 was mainly expressed in the cell cytoplasm and cell membrane ( Figure 1A ) consistent with the cellular immunofluorescence result ( Figure S1A ). The expression of OLR1 was significantly higher in the cancer tissues than in adjacent normal pancreatic tissues according to the IHC scores (P<0.001; Figure 1B ). The paired analysis of OLR1 IHC scores in 62 of the 99 cases with both cancer and adjacent tissues showed the same result (P<0.001; Figure 1C ). We also investigated the expression of OLR1 in pancreatic cancer samples from public databases (GSE28735 and GSE71729) and found that the level of OLR1 mRNA was upregulated in pancreatic cancer tissues compared with adjacent normal tissues ( Figure 1D and 1E).
We next evaluated the correlation between the level of OLR1 and clinicopathologic features. There was no significant correlation of OLR1 expression with gender, age, tumor location or T stage in pancreatic cancer patients. However, high expression of OLR1 was correlated with poor differentiation (P<0.05), increased lymph node metastasis (P<0.001) and advanced TNM staging (P<0.001) ( Table 1) , indicating that OLR1 level is related to metastasis.
Kaplan-Meier analysis revealed that pancreatic cancer patients with high OLR1 expression had a significantly worse median OS than those with low OLR1 expression (10 vs. 35 months, respectively; P=0.0095; Figure 1F ). Analysis of pancreatic cancer patients in the Cancer Genome Atlas (TCGA) and GSE28735 also revealed that high OLR1 mRNA expression correlated with poor prognosis of pancreatic cancer patients (P<0.05; Figure 1G and 1H). Univariate and multivariate analyses showed that OLR1 level was negatively correlated with OS in both analyses, indicating that high OLR1 expression is an independent prognostic risk factor for pancreatic cancer patients ( Table 2) . To determine the effect of OLR1 overexpression on cell proliferation, CCK-8 assay was performed as described in Methods by measuring the optical density at a wavelength of 450 nm as the relative cell number after adding CCK-8 agent into cells and culturing for an additional 2.5 h at 37°C. The growth rates of Bxpc-3 and Mia PaCa-2 pancreatic cancer cells transfected with OLR1 overexpression plasmids were significantly faster compared with control cells (P<0.0001; Figure 2A ) and the growth was inhibited when OLR1 was knocked down (P<0.0001; Figure 2B ). Transwell migration and invasion assays showed that OLR1 upregulation promoted migration and invasion of Bxpc-3 and Mia PaCa-2 cells and OLR1 knockdown in Bxpc-3 and Mia PaCa-2 cells inhibited cell migration and invasion (P<0.0001; Figure 2C ). Wound-healing assays also revealed that OLR1 overexpression increased but OLR1 knockdown decreased the migratory activity of both Bxpc-3 and Mia PaCa-2 cells compared with control cells ( Figure 2D and 2E). The effect of OLR1 knockdown and upregulation on OLR1 protein levels was verified by western blot ( Figure 2F ).
OLR1 promotes proliferation, migration and invasion of pancreatic cancer cells
Together these findings demonstrated that OLR1 promotes the proliferation, migration and invasion of pancreatic cancer cells in vitro.
OLR1 promotes the growth and invasion of pancreatic cancer cells in subcutaneous pancreatic cancer mouse models
To explore the effect of OLR1 inhibition of pancreatic cancer proliferation and invasion in vivo, we used a lentivirus system expressing shRNA to inhibit OLR1 expression (Lenti-shOLR1) or control lentivirus (Lenti-shCon) in Bxpc-3 cells. Lenti-shOLR1-and Lenti-shCon-infected Bxpc-3 cells were subcutaneously injected into the posterior flanks of nude mice. The growth of xenograft tumors in mice was monitored, and the mice were sacrificed five weeks after transplantation. Compared with control mice, the Lenti-shOLR1 group showed significantly suppressed tumor growth (P<0.05; Figure 3A ). Tumor weights were also lower in the OLR1 silenced group than in the control group (P<0.0001; Figure 3B ). H&E staining showed that OLR1 downregulation decreased the invasion of pancreatic cancer cells to adjacent muscle tissues ( Figure S1B ). We performed similar experiments using a lentivirus system overexpressing OLR1 (Lenti-OLR1). The tumor growth and tumor weights in the OLR1 upregulated mouse group were significantly higher than those in the control group ( Figure 3C and 3D). The invasion of pancreatic cancer cells to adjacent muscle tissues was also more apparent when OLR1 was increased ( Figure S1B ). OLR1 overexpression and knockdown was verified by IHC staining and western blot ( Figure  S1B-D) .
Together, these data demonstrated that OLR1 promotes the proliferation and invasion of Bxpc-3 pancreatic cancer cells in subcutaneous xenograft mouse models.
OLR1 inhibition suppresses the metastasis of pancreatic cancer cells in orthotopic, intrasplenic and intravenous pancreatic cancer models
To investigate whether OLR1 inhibition suppresses pancreatic cancer metastasis, we injected Bxpc-3 cells infected with Lenti-shOLR1 or Lenti-shCon orthotopically into the pancreas of SCID mice and monitored the growth of transplanted tumors by bioluminescence imaging. After five weeks, the group with OLR1 knockdown showed suppressed xenograft tumor growth compared with controls ( Figure 3E ). In mice injected with Lenti-shOLR1-expressing Bxpc-3 cells, the numbers of metastases in the liver, kidney, lung, spleen, abdominal and gut decreased dramatically compared with control mice ( Figure 3F and 3G ). All the metastases were validated by H&E staining ( Figure 3H ) and the downregulation of OLR1 expression was verified by IHC staining ( Figure S1E ).
To confirm the above results, we further injected Bxpc-3 cells infected with Lenti-shOLR1 or Lenti-shCon into the spleen of mice. The bioluminescence imaging and dissection results revealed fewer and smaller metastases in liver when OLR1 was knocked down compared with controls ( Figure 3I and 3J ). And the metastases were validated by H&E staining (Figure 3K and 3L) . Similarly, the bioluminescence imaging and dissection results of the intravenous mice also showed fewer and smaller metastases in lung when OLR1 was knocked down compared with controls ( Figure  S2A -D).
Together, these results indicate that inhibition of OLR1 leads to the decrease of metastatic capacity in pancreatic cancer cells.
OLR1 promotes the metastasis of pancreatic cancer cells by regulating c-Myc and HMGA2
To identify the transcriptome signature that may be involved in OLR1-mediated pancreatic cancer metastasis, we performed whole transcriptome RNA-sequencing (RNA-seq) analysis of Bxpc-3 cells with OLR1 overexpression or inhibition. In pancreatic cancer cells with OLR1 overexpression, there were 181 upregulated and 203 downregulated genes compared with control cells (by ≥2.0-fold change and P<0.05) ( Figure 4A ; Table S1 ). In cells with downregulation of OLR1, 179 genes were upregulated and 166 genes were downregulated compared with controls ( Figure  4A ; Table S1 ). To narrow down the genes specifically related to OLR1 expression, 26 genes positively correlated with OLR1 and 39 genes negatively correlated with OLR1 in both Lenti-OLR1 and Lenti-shOLR1 cells were chosen for further analysis ( Figure  4B ). Among these genes, COL4A4, HMGA2 and MYC are related to cancer metastasis, but only HMGA2 and MYC were positively correlated with OLR1 [22, 30] .
We next explored the relationships between OLR1 with c-Myc and HMGA2. qRT-PCR and western blot confirmed that c-Myc and HMGA2 mRNA and protein expressions were upregulated and inhibited when OLR1 was overexpressed or knocked down, respectively, in Bxpc-3 and Mia PaCa-2 cells ( Figure 4C -E; Figure  S3A -C). To further determine the clinical relevance, we investigated the expression of OLR1 along with c-Myc or HMGA2 in pancreatic cancer patients with RNA-seq data available from TCGA and confirmed that c-Myc and HMGA2 mRNA expressions were positively correlated with OLR1 expression (r=0.24, P<0.001, Figure 4F ; r=0.31, P<0.001, Figure 4G ) [31] .
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Author Manuscript Published OnlineFirst on February 4, 2020; DOI: 10.1158/1541-7786.MCR- was reduced upon transfection with siRNA targeting c-Myc (sic-Myc) or HMGA2 (siHMGA2) ( Figure 4H and 4I) . Similar results were obtained in transwell and invasion assays, which showed that c-Myc or HMGA2 overexpression prevented OLR1 inhibition-mediated effects on cell migration and invasion in Bxpc-3 cells ( Figure 4J and 4K) . We also observed similar results in Mia PaCa-2 cells ( Figure  S3D-G) .
Taken together, these data indicate that OLR1 promotes the metastasis of pancreatic cancer cells partly by inducing c-Myc and HMGA2 expression.
c-Myc promotes the transcription of HMGA2
Our results showed that ORL1 enhances c-Myc and HMGA2 expression at both mRNA and protein levels. c-Myc is a classical transcription factor and oncogene [32] . Therefore, we speculated that OLR1 may promote the transcription of HMGA2 through c-Myc. To verify our hypothesis, we examined the expression of HMGA2 in Bxpc-3 and Mia PaCa-2 cells with c-Myc silencing or overexpression and found that c-Myc increased the expression of HMGA2 at both mRNA and protein levels ( Figure  5A and 5B; Figure S4A and S4B). TCGA data also showed a positive correlation between c-Myc and HMGA2 (r=0.24, P<0.001; Figure 5C ). To determine whether c-Myc directly binds to the promoter of HMGA2, we first analyzed the human HMGA2 promoter region (-2000 bp ~ +1 bp) and identified two potential c-Myc binding sites containing the E box 5′-CACGTG-3′ sequence ( Figure 5D ). ENCODE (Encyclopedia of DNA Elements) c-Myc chromatin immunoprecipitation-sequencing (ChIP-seq) data showed that c-Myc was enriched at HMGA2 promoter regions in MCF10A human breast cells, HepG2 hepatocellular carcinoma cells and Gm12878 lymphocyte cells ( Figure 5E ) [27] . To verify whether c-Myc binds directly to these potential binding sites in the HMGA2 promoter, we performed a ChIP-qPCR assay in 293T, Bxpc-3 and Mia PaCa-2 cells. In chromatin fractions pulled down by anti-c-Myc antibody, the c-Myc binding elements 1 and 2 in the HMGA2 promoter were significantly increased compared with samples immunoprecipitated with control antibody (Figure 5F and 5G).
To further determine whether c-Myc activates the promoter of HMGA2, we constructed three luciferase reporter vectors driven by the HMGA2 wild-type promoter (WT) or HMGA2 mutant promoters (Mut1 and Mut2) ( Figure 5D ). Dual luciferase assays showed that the activities of HMGA2 WT and Mut2 promoters significantly increased when c-Myc was overexpressed ( Figure 5H ). However, activity of the HMGA2 Mut1 promoter showed no significant change with co-expression of c-Myc. In cells were co-transfected with HMGA2 WT and Mut2 reporters and sic-Myc, the luciferase activities were significantly inhibited, while the luciferase activity of HMGA2 Mut1 showed no changes with co-expression of sic-Myc ( Figure S4C ).
Together, these results show that c-Myc promotes the transcription of HMGA2 by directly binding to binding element 1 in the promoter of HMGA2. We next examined whether OLR1 increased transcription of HMGA2 through c-Myc is involved in the effects of OLR1 in promoting pancreatic cancer metastasis. We first examined whether c-Myc promotes invasion and metastasis of pancreatic cancer through increasing HMGA2. We transfected siHMGA2 in c-Myc-overexpressing Bxpc-3 and Mia Paca-2 cells and found that the increased migration and invasion activities from c-Myc overexpression were significantly inhibited in the absence of HMGA2 ( Figure 6A, Figure S5A ). HMGA2 overexpression also increased migration and invasion activities of Bxpc-3 and Mia Paca-2 cells with c-Myc knockdown ( Figure 6B, Figure S5B ). These results suggested that HMGA2 is required for the effect of c-Myc in promoting metastasis of pancreatic cancer cells. Previous studies indicated that EMT is closely related to metastasis, and therefore we explored whether HMGA2 regulates EMT to promote metastasis of pancreatic cancer cells. The results demonstrated that HMGA2 enhanced the expression of β-catenin and snail and inhibited E-cadherin level in Bxpc-3 and Mia PaCa-2 cells ( Figure 6C ), indicating that HMGA2 may promote metastasis by inducing EMT of pancreatic cancer cells.
OLR1 upregulates HMGA2 through c-Myc to promote pancreatic cancer
We next examined whether OLR1 regulation of HMGA2 occurred through c-Myc. The rescue result showed that HMGA2 induction by OLR1 overexpression was compromised by sic-Myc in Bxpc-3 and Mia PaCa-2 cells ( Figure 6D, Figure S5C ).
Together these data indicated that OLR1 increases the invasion and metastasis of pancreatic cancer cells by promoting the transcription of HMGA2 through c-Myc activity.
High OLR1, c-Myc and HMGA2 expression is associated with poor prognosis of pancreatic cancer patients
We next examined the clinical relationship of OLR1, c-Myc and HMGA2 levels by analyzing the expression of c-Myc and HMGA2 in TMAs containing the same patient tissues as the TMA used for OLR1 analysis. The expressions of c-Myc and HMGA2 were significantly higher in the OLR1 highly expressed group, and HMGA2 was significantly increased in the c-Myc highly expressed group, indicating that they are positively correlated with each other ( Figure 6E -H). IHC staining of subcutaneous and orthotopic xenograft tumors also revealed that the expressions of c-Myc and HMGA2 were positively correlated with the expression of OLR1 ( Figure S6A-S6B) . Kaplan-Meier survival analysis demonstrated that high expression of c-Myc and HMGA2 were each negatively correlated with the prognosis of pancreatic cancer patients in our cohort and TCGA ( Figure S7A-D) . When OLR1, c-Myc and HMGA2 were combined, Kaplan-Meier survival analysis showed the prognosis of patients with high expression of all three proteins was worse than that of patients with two highly expressed proteins, and the prognosis of patients with high expression of two of these proteins was worse compared with patients with high expression of only one or none of these proteins ( Figure 6I and Figure S7E -G). Analysis of TCGA data also revealed a similar result ( Figure 6J and Figure S7H-J) . These data revealed that the OLR1-c-Myc-HMGA2 axis may serve as prognostic markers for pancreatic cancer patients.
Discussion
In the present study, we explored the expression and role of OLR1 in pancreatic cancer. We first examined the expression of OLR1 in pancreatic cancer tissues and found that OLR1 expression was significantly higher in pancreatic cancer than in adjacent normal tissues. Clinicopathologic analysis showed that increased OLR1 expression was closely associated with poor differentiation, increased lymph node metastasis and TNM staging, as well as reduced OS. Inhibition of OLR1 expression decreased the proliferation and metastasis of pancreatic cancer cells both in vitro and in vivo. Mechanistically, OLR1 upregulated the expression of c-Myc to increase the transcription of HMGA2 gene, promoting the metastasis of pancreatic cancer. Finally, we revealed that the expression of OLR1, c-Myc and HMGA2 were positively correlated with each other in pancreatic cancer tissues and negatively correlated with the prognosis of pancreatic cancer patients. Altogether, these data demonstrated that OLR1 increases the proliferation and metastasis of pancreatic cancer cells by promoting the transcription of HMGA2 through c-Myc.
OLR1 has been closely related with cardiovascular and metabolic diseases. However, OLR1 was also recently reported to play an important role in cancer development, and the overexpression of OLR1 has been reported in multiple cancers, including pancreatic cancer. For example, Jie et al. reported that OLR1 is a poor prognostic indicator for pancreatic cancer and induced EMT which is consistent with our result; However, the authors did not explore the function and mechanism of OLR1 in pancreatic cancer metastasis [14] . To elucidate the mechanism of OLR1 in the metastasis of pancreatic cancer cells, we performed whole transcriptome RNA-seq analysis of Bxpc-3 cells with OLR1 stable overexpression or inhibition and found that c-Myc and HMGA2 were positively correlated with the level of OLR1. We further established that OLR1 promotes the metastasis of pancreatic cancer through c-Myc and HMGA2.
Previous reports showed that c-Myc and HMGA2 promote cancer metastasis as oncogenic factors [22, 30] , but the relationship between c-Myc and HMGA2 is rarely reported. Since c-Myc is a transcription factor, we speculated that OLR1 increased HMGA2 expression through c-Myc to promote metastasis of pancreatic cancer. We first demonstrated that the mRNA and protein levels of HMGA2 were regulated by c-Myc. Dual luciferase assay and ChIP assay confirmed that c-Myc promoted the transcription of HMGA2 by directly binding to its promoter through one of two potential binding sites. We also showed that HMGA2 was required for c-Myc-promoted invasion and metastasis of pancreatic cancer cells and that HMGA2 promoted EMT in pancreatic cancer cells. Together these results revealed that OLR1 increases invasion and metastasis of pancreatic cancer cells by promoting the transcription of HMGA2 through c-Myc.
The clinical significance of OLR1, c-Myc and HMGA2 was evaluated in pancreatic cancer tissues and TCGA database and the results showed that OLR1, c-Myc and HMGA2 were positively correlated with each other and negatively correlated with the prognosis of pancreatic cancer patients. Additionally, pancreatic cancer patients with on March 6, 2020. © 2020 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 4, 2020; DOI: 10.1158/1541-7786.MCR- high expression of all proteins showed worse prognosis compared with patients with high expression of two or fewer proteins. These data suggest that OLR1, c-Myc and HMGA2 might serve as potential prognosis markers for pancreatic cancer patients.
This study has several limitations. For example, the mechanism by which OLR1 promotes the expression of c-Myc is still unclear. Previous studies reported that OLR1 as a metabolism-and inflammation-related factor activates the NF-κB and PI3K/Akt pathways [11, 17] , which is related to the regulation of c-Myc [20] , indicating OLR1 may regulate c-Myc through these pathways. For example, previous studies identified OLR1 as one of the most upregulated lipid metabolism genes during cellular transformation, and inhibition of OLR1 reduced the activation of NF-κB through inhibition of IkB phosphorylation in cancer cells [16] . Furthermore, another study showed that overexpression of OLR1 induced the activation of NF-κB [9] . However, the transcription of c-Myc is directly regulated by NF-κB, the activation of which could promote the transcription of c-Myc [20, 33] . OLR1 was reported to drive PI3K/Akt/GSK3 activation [17] , which could enhance the expression of c-Myc [20] . Additionally, OLR1 may regulate the expression of HMGA2 and c-Myc through other mechanisms, such as miRNAs and lncRNAs [34] . For instance, HMGA2, c-Myc and OLR1 are targets of let-7 [18, 35] , and OLR1 may attenuate the inhibitory effect of let-7 on c-Myc and HMGA2 by competitive binding with let-7, thus promoting the expression of c-Myc and HMGA2. However, further studies are required to explore this possibility.
Although some lipid-lowering agents were reported to inhibit the level of OLR1, as a potential link between metabolic-cardiovascular diseases and cancer, no effective targeted drug for OLR1 is available [36] . The development of specific inhibitors targeting OLR1 will be useful to study the feasibility of OLR1 as a therapeutic target for pancreatic cancer in the future.
In conclusion, we identified the OLR1-c-Myc-HMGA2 axis as a pathway that promotes metastasis of pancreatic cancer and that may serve as potential therapeutic targets of metastasis and prognosis markers for pancreatic cancer patients. 
